Services
Expertises
Resources
Who we are
Open

FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award

Translational funding for Angelman syndrome research

Funding available
$ 1,000,000
Deadline
Open continuously
Location
Canada
Who can apply
Nonprofit research institutions
See full eligibility

Overview

Supports translational Angelman syndrome research toward clinical trials. Funding is up to $1,000,000 per year for innovative, high-impact studies and IND-enabling work.

At a glance

Funding available

Maximum funding
$1,000,000
Financing goals
  • Develop a new program or service
  • Enhance an existing program
  • Conduct research and development activities
  • Conduct research or evaluation activities

Eligible candidates

Location
  • Canada
Eligible Industries
All industries
Annual revenue
All revenue ranges
Organisation size
All organization sizes
Audience
All groups
Legal structures
Non-profit
Non-profit candidates
Sector of operation
Research
Target groups
Nonprofits / charities, Academia / students
Revenue structures
100% donations / grants
Scope
National, International

Start applying for this program

Take a practical assessment to gain a clear understanding of how well this program aligns with your specific needs and long-term goals.

Availability timeline

2026
Periods: 1

Latest changes

FAST IMPACT award policies updated

The IMPACT Award page now presents a fuller policies document with updated submission guidance, added review rules, and clearer application requirements.

See more

The IMPACT Award content has been expanded into a detailed policies document that adds new sections on key dates, similar applications, human and animal subjects, grant review, no-cost extensions, carry-forward, and nondiscrimination. It also updates application instructions, including the LOI and submission email, PDF-only review, and a more explicit required-outline structure. The core award purpose and funding level remain centered on translational Angelman syndrome research up to the IND-enabling stage, but the process and compliance requirements are now much more fully specified.

Eligibility

Who is eligible?

  • Nonprofit research institutions
  • Academic investigators
  • Scientists and clinicians with PhD- or MD-level training

Who is not eligible

  • For-profit institutions
  • Applicants without PhD- or MD-level training and experience

Eligible expenses

  • Reagents and research materials
  • External research services
  • Specialized equipment or software
  • Personnel salaries and fringe benefits
  • Travel to the FAST scientific symposium

Ineligible Costs and Activities

  • Indirect costs on tuition, equipment, software, or software licenses
  • Applications with the same research focus from the same applicant organization on the same submission date

Activities funded

  • Translational research platform projects for Angelman syndrome
  • Pre-clinical studies advancing toward IND-enabling work
  • Studies of pharmacological, biologic, gene-editing, or gene-replacement therapies
  • Repurposing of approved or clinically safe therapies for Angelman syndrome

How to apply

  • Step 1: Submit Letter of Intent
    • Send an LOI to FAST before applying.
    • Include the project summary, budget estimate, duration, preliminary data, and CV or biosketch.
  • Step 2: Prepare the application package
    • Complete the FAST application form and research plan.
    • Include the budget, budget justification, other support, facilities, and biosketch documents.
  • Step 3: Submit electronically
    • Upload the application through the electronic submission link.
    • Submit the materials as PDF files.

Documents Needed

  • Letter of Intent
  • Research plan
  • Budget and budget justification
  • CV or NIH biosketch
  • Other support information

Selection criteria

  • Scientific merit
  • Innovation
  • Translational impact
  • Alignment with FAST’s mission
  • Feasibility and experimental design

Processing and Agreement

  • Applications are first reviewed by the Scientific Advisory Board.
  • Applications are scored for scientific merit, innovation, translational impact, and mission alignment.
  • Recommendations are reviewed by the Scientific Director Panel.
  • Final approval is made by the FAST Board of Directors.
  • Applicants may need to respond to SAB questions or recommendations before a final decision.

Additional information

  • Applications are accepted on a rolling basis.
  • A Letter of Intent is required before applying.
  • Projects longer than one year require annual renewal.

Contacts

Official sources

Add helloDarwin as a preferred source on Google

Frequently Asked Questions about the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award Program

What is the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award?

Supports translational Angelman syndrome research toward clinical trials. Funding is up to $1,000,000 per year for innovative, high-impact studies and IND-enabling work.

How much funding can be received?

FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award Funds up to $1,000,000 of admissible expenses.

What is the deadline to apply?

The program is accepting continuous intake

Who is eligible for the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award program?

To be eligible for the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award program, you must: Nonprofit institution required. PhD- or MD-level applicant. Full-time research commitment.

What expenses are eligible under FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award?

Reagents and research materials External research services Specialized equipment or software Personnel salaries and fringe benefits Travel to the FAST scientific symposium

Who can I contact for more information about the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award?

You can contact Foundation for Angelman Syndrome Therapeutics (FAST) by email at science@cureangelman.org or by phone at 630-852-3278.

Where is the FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award available?

The FAST IMPACT (Innovative Methods to Advance Angelman Syndrome Treatments Towards Clinical Trials) Award program is available across Canada.